Diabetes Devices: All Eyes on Patch-Pumps

article image

With the recent success of Insulet’s new Omnipod 5 automated insulin delivery patch pump, there is renewed focus on the patch-pump opportunity, and competitors, including Tandem Diabetes Care, are leading the charge.

One of the most significant diabetes device stories of 2022 was the US launch of Insulet’s much-anticipated Omnipod 5, the first insulin patch-pump system with hybrid closed-loop automated insulin delivery (AID) capabilities. Since the launch there has been strong demand for Omnipod 5 among both existing and new pump users, impacting the competitive landscape and focusing renewed attention on the patch-pump opportunity.

Worn on the body for a period of days, tubeless patch pumps such as Omnipod are simpler to operate and have lower up-front costs than traditional tubed insulin pumps. The Omnipod 5, which further simplifies glucose management by adding an AID algorithm, appears to have struck a chord with both patients and physicians, and Insulet’s competitors are taking note. One major player in the pump field—Tandem Diabetes Care—is already shoring up its patch-pump pipeline with a deal to acquire a private Swiss company developing a novel patch pump, and there could be similar announcements in the future as competition in this space heats up.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: